Eliot Forster - Sep 14, 2023 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role
Director
Signature
/s/ Eyal Rubin, POA
Stock symbol
PLX
Transactions as of
Sep 14, 2023
Transactions value $
$0
Form type
4
Date filed
9/15/2023, 04:46 PM
Previous filing
Mar 9, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLX Stock Options (Right to Buy) Award $0 +85.7K $0.00 85.7K Sep 14, 2023 Common Stock 85.7K $1.75 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.